Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2011

View Archived Issues

Interim first-in-human data released on two c-Met inhibitors

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Halozyme discloses clinical results on new Herceptin formulation

Pulmonary Fibrosis Foundation to fund independent evaluation of Compugen's candidate for IPF

Orantinib advances through studies in NSCLC and breast cancer

U.S. universities assess CDME in model of cystinuria

Analyses focus on cardiovascular risk with naltrexone/bupropion

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Phase I study of PPI-668 commences

CSIR presents new antitumor agents

Takeda commences international phase III program for TAK-875

Lpath begins dosing in second proof-of-concept iSONEP trial

Studies confirm efficacy of Transcend-trastuzumab conjugate in HER2-positive breast cancer

Encore Therapeutics completes proof-of-concept study of ETI-511

Novel vitamin D receptor ligands synthesized at WARF

FDA clears IsoAmp HSV assay

Nile Therapeutics completes dosing in subcutaneous cenderitide trial

Phase I MultiStem study advances

Actelion Pharmaceuticals reports new prostanoid DP2 receptor antagonists

FDA approves MethylGene's IND for new study of antifungal product candidate

Lux Biosciences withdraws Luveniq MAA

Almirall and Lundbeck enter agreement to copromote escitalopram

EMA delays review of Flutiform MAA

Isotechnika receives scientific advice from EMA for voclosporin trial

Malaria vaccine RTS,S/ASO1E shows efficacy in African children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...